US 12,357,226 B2
Determining medical staffing for oral immunotherapy
Hans Chuang, Brisbane, CA (US); Brian Greenblatt, Brisbane, CA (US); Richard Smith, Brisbane, CA (US); Marisa Crowell, Brisbane, CA (US); Varsha Damle, Brisbane, CA (US); Chantale Bielak, Toronto (CA); Robert Grossi, Toronto (CA); and Joy Mabon, Toronto (CA)
Assigned to Société des Produits Nestlé S.A., Vevey (CH)
Filed by Société des Produits Nestlé S.A., Vevey (CH)
Filed on Jun. 30, 2021, as Appl. No. 17/364,518.
Claims priority of provisional application 63/047,216, filed on Jul. 1, 2020.
Prior Publication US 2022/0000416 A1, Jan. 6, 2022
Int. Cl. A61B 5/00 (2006.01); G16H 20/10 (2018.01); G16H 40/20 (2018.01)
CPC A61B 5/411 (2013.01) [A61B 5/4848 (2013.01); A61B 5/742 (2013.01); G16H 20/10 (2018.01); G16H 40/20 (2018.01)] 10 Claims
OG exemplary drawing
 
1. A method for determining medical staffing requirements for administering an oral immunotherapy (OIT) for peanut allergy to patients at a treatment location, wherein the OIT for peanut allergy comprises an up-dosing protocol and one or more maintenance doses, the method comprising:
1) Receiving:
i) a number of patients starting the OIT per a selected time period at a treatment location;
ii) a number of visits to the treatment location to complete the up-dosing protocol and/or the one or more maintenance doses;
iii) an amount of time between visits to the treatment location to complete the up-dosing protocol and/or the one or more maintenance doses;
iv) a number of rooms or areas available at the treatment location designated for the OIT for peanut allergy; and
v) a number of medical staff present at the treatment location;
2) Determining:
i) an estimated amount of time required by the number of medical staff to administer the up-dosing protocol and/or the one or more maintenance doses, comprising:
a first estimated amount of time to administer an initial dose escalation (IDE) of the up-dosing protocol for each new patient and which of these patients can be monitored as a group;
a second estimated amount of time to administer each subsequent dose of a dose escalation of the up-dosing protocol and which of these patients can be monitored as a group;
ii) an available treatment time for the number of rooms or areas over the selected time period;
iii) a number of visits to the treatment location required for each patient to complete the up-dosing protocol and/or one or more maintenance doses;
iv) an amount of time between visits to the treatment location for each patient after the current administration by the medical staff;
v) an amount of time to administer a subsequent dose for each patient;
vi) a percentage of patients who completed the up-dosing protocol and/or one or more maintenance doses;
vii) when the time required by the number of medical staff to administer the up-dosing protocol and/or the one or more maintenance doses to the patients exceeds the available treatment time for all rooms or areas at the treatment location designated for the OIT for peanut allergy over the selected period of time; and
vii when steady state occurs, wherein steady state is when a rate of new patients equals a rate of patients completing the OIT; and
3) displaying, using a graphical indication,
i) the estimated amount of time for the number of medical staff to administer the up-dosing protocol and/or the one or more maintenance doses to each patient and the room or area at the treatment location for administration over the selected time period;
ii) the available treatment time for each room or area dedicated to the OIT over the selected time period;
iii) the number of visits to the treatment location required for each patient to complete the up-dosing protocol and/or one or more maintenance doses after the current administration;
iv) the amount of time to administer the subsequent dose for each patient;
v) the amount of time between visits to the treatment location for each patient after the current administration by the medical staff;
vi) the number of patients undergoing the OIT at the treatment location over the selected time period;
vii) the percentage of patients who completed the up-dosing protocol and/or one or more maintenance doses after the administration;
viii) that the time required by the number of medical staff to administer the up-dosing protocol and/or the one or more maintenance doses to the patients exceeds the available treatment time for all rooms or areas at the treatment location designated for the OIT for peanut allergy over the selected period of time; and
vix) if steady state occurs and the number of patients undergoing OIT at steady state.